NCT07127497View on ClinicalTrials.gov

Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2028

Conditions
Objective Response Rate for Neoadjuvant Chemotherapy, ORR
Interventions
BIOLOGICAL

Sintilimab combined with XELOX

Sintilimab (3 mg/kg, IV, qd for patients with body weight \< 60 kg; 200 mg, IV, qd for patients with body weight ≥ 60 kg) combined with XELOX (oxaliplatin 130 mg/m2, IV, qd + capecitabine 1000 mg/m2, bid, d1 - d14, q21d) for 2-4 courses

Trial Locations (1)

230022

The First Affiliated Hospital of Anhui Medical University, Hefei

All Listed Sponsors
lead

The First Affiliated Hospital of Anhui Medical University

OTHER